FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says
Executive Summary
FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai
You may also be interested in...
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control
Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis
FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies